肾功能与癌症风险之间的因果关系:孟德尔随机研究。

IF 9.4 1区 医学 Q1 UROLOGY & NEPHROLOGY
Ellen Dobrijevic , Anita van Zwieten , Andrew J. Grant , Clement T. Loy , Jonathan C. Craig , Armando Teixeira-Pinto , Germaine Wong
{"title":"肾功能与癌症风险之间的因果关系:孟德尔随机研究。","authors":"Ellen Dobrijevic ,&nbsp;Anita van Zwieten ,&nbsp;Andrew J. Grant ,&nbsp;Clement T. Loy ,&nbsp;Jonathan C. Craig ,&nbsp;Armando Teixeira-Pinto ,&nbsp;Germaine Wong","doi":"10.1053/j.ajkd.2024.05.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><div>Patients treated with kidney replacement therapy experience a 1.5- to 2-fold increased risk of cancer and cancer mortality compared with the general population. Whether this excess risk extends to people with earlier stage chronic kidney disease and whether reduced kidney function is causally related to cancer is unclear.</div></div><div><h3>Study Design</h3><div>Two-sample Mendelian randomization (MR).</div></div><div><h3>Setting &amp; Participants</h3><div>Genome-wide association study (GWAS) summary statistics for estimated glomerular filtration rate (eGFR) (n<!--> <!-->=<!--> <!-->567,460) and urinary albumin-creatine ratio (UACR) (n<!--> <!-->=<!--> <!-->127,865) from the CKDGen consortium and cancer outcomes from the UK Biobank (n = 407,329).</div></div><div><h3>Exposure</h3><div>eGFR and UACR.</div></div><div><h3>Outcome</h3><div>Overall cancer incidence, cancer-related mortality and site-specific colorectal, lung, and urinary tract cancer incidence.</div></div><div><h3>Analytical Approach</h3><div>Univariable and multivariable MR conducted for all outcomes.</div></div><div><h3>Results</h3><div>The mean eGFR and median UACR were 91.4<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup> and 9.32<!--> <!-->mg/g, respectively, in the CKDGen, and 90.4<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup> and 9.29<!--> <!-->mg/g, respectively, in the UK Biobank. There were 98,093 cases of cancer, 15,850 cases of cancer-related death, 6,664 colorectal, 3584 lung, and 3,271 urinary tract cancer cases, respectively. The genetic instruments for eGFR and UACR comprised 34 and 38 variants, respectively. Genetically predicted kidney function (eGFR and UACR) was not associated with overall cancer risk or cancer death. The association between genetically predicted eGFR and UACR and overall cancer incidence had an odds ratio of 0.88 ([95% CI, 0.40-1.97], <em>P</em> <!-->=<!--> <!-->0.8) and 0.90 ([95% CI, 0.78-1.04], <em>P</em> <!-->=<!--> <!-->0.2) respectively, using the inverse-variance weighted method. An adjusted generalized additive model for eGFR and cancer demonstrated evidence of nonlinearity. However, there was no evidence of a causal association between eGFR and cancer in a stratified MR.</div></div><div><h3>Limitations</h3><div>To avoid overlapping samples a smaller GWAS for UACR was used, which reduced the strength of the instrument and may introduce population stratification.</div></div><div><h3>Conclusions</h3><div>Our study did not show a causal association between kidney function, overall cancer incidence, and cancer-related death.</div></div><div><h3>Plain-Language Summary</h3><div>Does reduced kidney function cause cancer? Patients with chronic kidney disease have been shown to have an increased risk of cancer and cancer-related death. However, it is not clear whether kidney disease is causally related to cancer or the association is due to other factors such as immune suppression and inflammation or a result of distortion of the analyses from unidentified variables (confounding). We used large, published genetic studies as well a database including 407,329 people in the United Kingdom in a series of Mendelian randomization analysis. Mendelian randomization uses the random assignment of genetic variants at birth to investigate causal relationships without confounding from measured and unmeasured confounders. We found that there is no evidence of a causal relationship between reduced kidney function and cancer.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"84 6","pages":"Pages 686-695.e1"},"PeriodicalIF":9.4000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Causal Relationship Between Kidney Function and Cancer Risk: A Mendelian Randomization Study\",\"authors\":\"Ellen Dobrijevic ,&nbsp;Anita van Zwieten ,&nbsp;Andrew J. Grant ,&nbsp;Clement T. Loy ,&nbsp;Jonathan C. Craig ,&nbsp;Armando Teixeira-Pinto ,&nbsp;Germaine Wong\",\"doi\":\"10.1053/j.ajkd.2024.05.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Rationale &amp; Objective</h3><div>Patients treated with kidney replacement therapy experience a 1.5- to 2-fold increased risk of cancer and cancer mortality compared with the general population. Whether this excess risk extends to people with earlier stage chronic kidney disease and whether reduced kidney function is causally related to cancer is unclear.</div></div><div><h3>Study Design</h3><div>Two-sample Mendelian randomization (MR).</div></div><div><h3>Setting &amp; Participants</h3><div>Genome-wide association study (GWAS) summary statistics for estimated glomerular filtration rate (eGFR) (n<!--> <!-->=<!--> <!-->567,460) and urinary albumin-creatine ratio (UACR) (n<!--> <!-->=<!--> <!-->127,865) from the CKDGen consortium and cancer outcomes from the UK Biobank (n = 407,329).</div></div><div><h3>Exposure</h3><div>eGFR and UACR.</div></div><div><h3>Outcome</h3><div>Overall cancer incidence, cancer-related mortality and site-specific colorectal, lung, and urinary tract cancer incidence.</div></div><div><h3>Analytical Approach</h3><div>Univariable and multivariable MR conducted for all outcomes.</div></div><div><h3>Results</h3><div>The mean eGFR and median UACR were 91.4<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup> and 9.32<!--> <!-->mg/g, respectively, in the CKDGen, and 90.4<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup> and 9.29<!--> <!-->mg/g, respectively, in the UK Biobank. There were 98,093 cases of cancer, 15,850 cases of cancer-related death, 6,664 colorectal, 3584 lung, and 3,271 urinary tract cancer cases, respectively. The genetic instruments for eGFR and UACR comprised 34 and 38 variants, respectively. Genetically predicted kidney function (eGFR and UACR) was not associated with overall cancer risk or cancer death. The association between genetically predicted eGFR and UACR and overall cancer incidence had an odds ratio of 0.88 ([95% CI, 0.40-1.97], <em>P</em> <!-->=<!--> <!-->0.8) and 0.90 ([95% CI, 0.78-1.04], <em>P</em> <!-->=<!--> <!-->0.2) respectively, using the inverse-variance weighted method. An adjusted generalized additive model for eGFR and cancer demonstrated evidence of nonlinearity. However, there was no evidence of a causal association between eGFR and cancer in a stratified MR.</div></div><div><h3>Limitations</h3><div>To avoid overlapping samples a smaller GWAS for UACR was used, which reduced the strength of the instrument and may introduce population stratification.</div></div><div><h3>Conclusions</h3><div>Our study did not show a causal association between kidney function, overall cancer incidence, and cancer-related death.</div></div><div><h3>Plain-Language Summary</h3><div>Does reduced kidney function cause cancer? Patients with chronic kidney disease have been shown to have an increased risk of cancer and cancer-related death. However, it is not clear whether kidney disease is causally related to cancer or the association is due to other factors such as immune suppression and inflammation or a result of distortion of the analyses from unidentified variables (confounding). We used large, published genetic studies as well a database including 407,329 people in the United Kingdom in a series of Mendelian randomization analysis. Mendelian randomization uses the random assignment of genetic variants at birth to investigate causal relationships without confounding from measured and unmeasured confounders. We found that there is no evidence of a causal relationship between reduced kidney function and cancer.</div></div>\",\"PeriodicalId\":7419,\"journal\":{\"name\":\"American Journal of Kidney Diseases\",\"volume\":\"84 6\",\"pages\":\"Pages 686-695.e1\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Kidney Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0272638624008953\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0272638624008953","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

理由和目标:与普通人群相比,接受肾脏替代疗法的患者罹患癌症和癌症死亡率的风险会增加 1.5 到 2 倍。至于慢性肾脏病早期患者是否也存在这种超额风险,目前尚不清楚。本研究探讨了肾功能减退与癌症之间的潜在因果关系:双样本孟德尔随机化(MR):全基因组关联研究(GWAS)汇总统计了来自CKDGen联盟的估算肾小球滤过率(eGFR)(n=567,460)和尿白蛋白尿(UACR)(n=127,865),以及来自英国生物库(UK Biobank)的癌症结果(n=407,329):结果:总体癌症发病率、癌症相关死亡率、特定部位结直肠癌、肺癌和尿路癌发病率:分析方法:采用逆方差加权法对所有结果进行单变量和多变量 MR 分析:CKDGen的平均eGFR和中位UACR分别为91.4 mL/min/1.73m2和9.32 mg/g,英国生物库的平均eGFR和中位UACR分别为90.4 mL/min/1.73m2和9.29 mg/g。共有 98093 例癌症病例,其中 6664 例为结直肠癌,3584 例为肺癌,3271 例为尿道癌。癌症相关死亡病例为 15850 例,eGFR 和 UACR 的基因工具分别包括 34 个和 38 个变体。基因预测的肾功能(eGFR 和 UACR)与总体癌症风险或癌症死亡无关。基因预测的 eGFR 和 UACR 与癌症总发病率没有关联;几率比(95%CI;p 值)分别为 0.88(0.40-1.97;p=0.76)和 0.90(0.78-1.04;p=0.16)。经调整的 eGFR 与癌症的广义相加模型显示出非线性的证据。在分层 MR 中,没有证据表明 eGFR 与癌症之间存在因果关系:为避免样本重叠,使用了较小的 UACR GWAS,从而降低了工具的强度,并可能引入人群分层:这些发现并未证明肾功能与癌症总发病率或癌症相关死亡之间存在因果关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Causal Relationship Between Kidney Function and Cancer Risk: A Mendelian Randomization Study

Causal Relationship Between Kidney Function and Cancer Risk: A Mendelian Randomization Study

Rationale & Objective

Patients treated with kidney replacement therapy experience a 1.5- to 2-fold increased risk of cancer and cancer mortality compared with the general population. Whether this excess risk extends to people with earlier stage chronic kidney disease and whether reduced kidney function is causally related to cancer is unclear.

Study Design

Two-sample Mendelian randomization (MR).

Setting & Participants

Genome-wide association study (GWAS) summary statistics for estimated glomerular filtration rate (eGFR) (n = 567,460) and urinary albumin-creatine ratio (UACR) (n = 127,865) from the CKDGen consortium and cancer outcomes from the UK Biobank (n = 407,329).

Exposure

eGFR and UACR.

Outcome

Overall cancer incidence, cancer-related mortality and site-specific colorectal, lung, and urinary tract cancer incidence.

Analytical Approach

Univariable and multivariable MR conducted for all outcomes.

Results

The mean eGFR and median UACR were 91.4 mL/min/1.73 m2 and 9.32 mg/g, respectively, in the CKDGen, and 90.4 mL/min/1.73 m2 and 9.29 mg/g, respectively, in the UK Biobank. There were 98,093 cases of cancer, 15,850 cases of cancer-related death, 6,664 colorectal, 3584 lung, and 3,271 urinary tract cancer cases, respectively. The genetic instruments for eGFR and UACR comprised 34 and 38 variants, respectively. Genetically predicted kidney function (eGFR and UACR) was not associated with overall cancer risk or cancer death. The association between genetically predicted eGFR and UACR and overall cancer incidence had an odds ratio of 0.88 ([95% CI, 0.40-1.97], P = 0.8) and 0.90 ([95% CI, 0.78-1.04], P = 0.2) respectively, using the inverse-variance weighted method. An adjusted generalized additive model for eGFR and cancer demonstrated evidence of nonlinearity. However, there was no evidence of a causal association between eGFR and cancer in a stratified MR.

Limitations

To avoid overlapping samples a smaller GWAS for UACR was used, which reduced the strength of the instrument and may introduce population stratification.

Conclusions

Our study did not show a causal association between kidney function, overall cancer incidence, and cancer-related death.

Plain-Language Summary

Does reduced kidney function cause cancer? Patients with chronic kidney disease have been shown to have an increased risk of cancer and cancer-related death. However, it is not clear whether kidney disease is causally related to cancer or the association is due to other factors such as immune suppression and inflammation or a result of distortion of the analyses from unidentified variables (confounding). We used large, published genetic studies as well a database including 407,329 people in the United Kingdom in a series of Mendelian randomization analysis. Mendelian randomization uses the random assignment of genetic variants at birth to investigate causal relationships without confounding from measured and unmeasured confounders. We found that there is no evidence of a causal relationship between reduced kidney function and cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American Journal of Kidney Diseases
American Journal of Kidney Diseases 医学-泌尿学与肾脏学
CiteScore
20.40
自引率
2.30%
发文量
732
审稿时长
3-8 weeks
期刊介绍: The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信